Tucatinib Together With Pembrolizumab and Trastuzumab
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Women or men with HER2-positive, metastatic breast cancer, who have progressed on previous
treatment, will receive tucatinib in combination with:
- Pembrolizumab and trastuzumab (PD-L1 positive); or
- Pembrolizumab, trastuzumab and capecitabine (PD-L1 negative)